205 related articles for article (PubMed ID: 21971332)
21. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
22. Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.
Koldej RM; Carney G; Wielgosz MM; Zhou S; Zhan J; Sorrentino BP; Nienhuis AW
Hum Gene Ther Clin Dev; 2013 Jun; 24(2):77-85. PubMed ID: 23786330
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for Wiskott-Aldrich Syndrome.
Bosticardo M; Ferrua F; Cavazzana M; Aiuti A
Curr Gene Ther; 2014; 14(6):413-21. PubMed ID: 25245089
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
[TBL] [Abstract][Full Text] [Related]
25. Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions.
Ferrua F; Marangoni F; Aiuti A; Roncarolo MG
J Allergy Clin Immunol; 2020 Aug; 146(2):262-265. PubMed ID: 32623069
[No Abstract] [Full Text] [Related]
26. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
[TBL] [Abstract][Full Text] [Related]
27. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
Naseem A; Steinberg Z; Cavazza A
Front Immunol; 2022; 13():966084. PubMed ID: 36059471
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.
Bosticardo M; Marangoni F; Aiuti A; Villa A; Grazia Roncarolo M
Blood; 2009 Jun; 113(25):6288-95. PubMed ID: 19351959
[TBL] [Abstract][Full Text] [Related]
29. The genotype of the original Wiskott phenotype.
Binder V; Albert MH; Kabus M; Bertone M; Meindl A; Belohradsky BH
N Engl J Med; 2006 Oct; 355(17):1790-3. PubMed ID: 17065640
[TBL] [Abstract][Full Text] [Related]
30. [Wiskott-Aldrich syndrome].
Gulácsy V; Maródi L
Orv Hetil; 2008 Jul; 149(29):1367-71. PubMed ID: 18617469
[TBL] [Abstract][Full Text] [Related]
31. Wiskott Aldrich Syndrome: A Multi-Institutional Experience From India.
Suri D; Rikhi R; Jindal AK; Rawat A; Sudhakar M; Vignesh P; Gupta A; Kaur A; Sharma J; Ahluwalia J; Bhatia P; Khadwal A; Raj R; Uppuluri R; Desai M; Taur P; Pandrowala AA; Gowri V; Madkaikar MR; Lashkari HP; Bhattad S; Kumar H; Verma S; Imai K; Nonoyama S; Ohara O; Chan KW; Lee PP; Lau YL; Singh S
Front Immunol; 2021; 12():627651. PubMed ID: 33936041
[TBL] [Abstract][Full Text] [Related]
32. Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.
Uchiyama T; Adriani M; Jagadeesh GJ; Paine A; Candotti F
Mol Ther; 2012 Jun; 20(6):1270-9. PubMed ID: 22215016
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
[TBL] [Abstract][Full Text] [Related]
34. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
[TBL] [Abstract][Full Text] [Related]
35. Wiskott-Aldrich syndrome; an x-linked primary immunodeficiency disease with unique and characteristic features.
Ariga T
Allergol Int; 2012 Jun; 61(2):183-9. PubMed ID: 22361515
[TBL] [Abstract][Full Text] [Related]
36. How I manage patients with Wiskott Aldrich syndrome.
Rivers E; Worth A; Thrasher AJ; Burns SO
Br J Haematol; 2019 May; 185(4):647-655. PubMed ID: 30864154
[TBL] [Abstract][Full Text] [Related]
37. New insights into the biology of Wiskott-Aldrich syndrome (WAS).
Thrasher AJ
Hematology Am Soc Hematol Educ Program; 2009; ():132-8. PubMed ID: 20008191
[TBL] [Abstract][Full Text] [Related]
38. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
39. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome.
Sereni L; Castiello MC; Di Silvestre D; Della Valle P; Brombin C; Ferrua F; Cicalese MP; Pozzi L; Migliavacca M; Bernardo ME; Pignata C; Farah R; Notarangelo LD; Marcus N; Cattaneo L; Spinelli M; Giannelli S; Bosticardo M; van Rossem K; D'Angelo A; Aiuti A; Mauri P; Villa A
J Allergy Clin Immunol; 2019 Sep; 144(3):825-838. PubMed ID: 30926529
[TBL] [Abstract][Full Text] [Related]
40. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
